loader
Please Wait
Applying Filters...
menu
    • menu

    Digital Content for Revumenib

    Client Email Product
    EUROAPI, the leading small molecules API player, provides both API sales & CDMO services.

    Virtual Booth

    Contact Supplier

    Bora Pharmaceuticals- Making success more certain.

    Virtual Booth

    Contact Supplier

    Polfa Tarchomin is a leading Polish pharmaceutical company with 200 year tradition in manufacture and sale of pharmaceutical products.

    Virtual Booth

    Contact Supplier

    Minakem offers CDMO services for API & HPAPI, generics, regulatory expertise, track record performance & FDA & GMP certifications.

    Virtual Booth

    Contact Supplier

    Axplora- The partner of choice for complex APIs.

    Virtual Booth

    Contact Supplier

    Fareva is a one-stop-shop for API/HPAPI, OSD & Sterile products, is USFDA, EMA and PMDA-inspected and has multiple NDA & ANDA filings.

    Virtual Booth

    Contact Supplier

    Menu

    Revumenib

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    PRICE INFORMATION

    DIGITAL CONTENT

    PharmaCompass
    $ API Ref.Price (USD/KG) : 3,631Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Syndax Publishes AUGMENT-101 Trial Data On Revumenib In Leukemia
    Syndax Publishes AUGMENT-101 Trial Data On Revumenib In Leukemia

    12 Aug 2024

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/syndax-announces-publication-in-the-journal-of-clinical-oncology-of-data-from-the-pivotal-augment-101-trial-of-revumenib-in-relapsedrefractory-kmt2ar-acute-leukemia-302219402.html

    PR NEWSWIRE
    12 Aug 2024
    Share Share
    Syndax Announces PDUFA Date Extension For Revumenib In Acute Leukemia
    Syndax Announces PDUFA Date Extension For Revumenib In Acute Leukemia

    29 Jul 2024

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/syndax-announces-pdufa-action-date-extension-for-revumenib-nda-for-relapsed-or-refractory-kmt2ar-acute-leukemia-302208308.html

    PR NEWSWIRE
    29 Jul 2024
    Share Share
    Syndax Presents Updated Revumenib Data At EHA 2024
    Syndax Presents Updated Revumenib Data At EHA 2024

    14 Jun 2024

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/syndax-presents-updated-positive-data-from-beat-aml-and-augment-102-phase-12-combination-trials-of-revumenib-in-patients-with-acute-leukemias-at-eha-2024-congress-302172942.html

    PR NEWSWIRE
    14 Jun 2024
    Share Share
    Syndax Plans Phase 1b Trial Of Revumenib In Relapsed/Refractory MSS CRC
    Syndax Plans Phase 1b Trial Of Revumenib In Relapsed/Refractory MSS CRC

    06 Jun 2024

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/syndax-announces-plans-to-advance-into-phase-1b-portion-of-trial-evaluating-revumenib-in-relapsed-or-refractory-metastatic-mss-crc-302165405.html

    PR NEWSWIRE
    06 Jun 2024
    Share Share
    Syndax Presents Positive Data from Pivotal AUGMENT-101 Trial
    Syndax Presents Positive Data from Pivotal AUGMENT-101 Trial

    08 Apr 2024

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/syndax-presents-positive-pediatric-data-from-pivotal-augment-101-trial-of-revumenib-in-relapsedrefractory-kmt2ar-acute-leukemia-at-aspho-plenary-session-302109899.html

    PR NEWSWIRE
    08 Apr 2024
    Share Share
    Syndax FDA Priority Review of NDA for Revumenib Relapsed/Refractory KMT2Ar
    Syndax FDA Priority Review of NDA for Revumenib Relapsed/Refractory KMT2Ar

    26 Mar 2024

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/syndax-announces-fda-priority-review-of-nda-for-revumenib-for-the-treatment-of-relapsedrefractory-kmt2ar-acute-leukemia-302100145.html

    PR NEWSWIRE
    26 Mar 2024
    Share Share